View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 4, 2020updated 04 Aug 2022 1:42pm

The hydroxychloroquine debate continues

By Miranda Mclaren

Hydroxychloroquine is an immunosuppressive drug approved for the treatment of malaria and repeatedly praised by US President Donald Trump, who claims to have taken it to ward off Covid-19. The US recently sent two million doses of hydroxychloroquine to Brazil to fight Covid-19, however, the use of hydroxychloroquine as a treatment in Covid-19 clinical trials is currently under debate. A study published by The Lancet on 22 May 2020 showed that hydroxychloroquine increased the risk of death in Covid-19 patients.

Currently, there are 398 Covid-19 clinical trials using hydroxychloroquine and/or chloroquine as a primary or secondary intervention, signalling more data are on the way to determine if hydroxychloroquine is an effective treatment against Covid-19.

To read more, please click here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena